These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16506347)

  • 1. Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents.
    Brouillard JE; Terriff CM; Tofan A; Garrison MW
    Pharmacotherapy; 2006 Jan; 26(1):3-14. PubMed ID: 16506347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fluoroquinolones: antimicrobial activity and chemotherapeutic efficacy with respect to various pathogens in highly dangerous diseases].
    Bondareva TA; Kalininskiĭ VB; Borisevich IV; Bondarev VP; Kozhukhov VV; Amosov MIu; Baramzina GV; Fomenkov OO; Krinitsyn FV
    Antibiot Khimioter; 2007; 52(11-12):21-4. PubMed ID: 19275053
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Germs and toxins in bioterrorism].
    Inoue N
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():81-91. PubMed ID: 12722194
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents.
    Greenfield RA; Bronze MS
    Drug Discov Today; 2003 Oct; 8(19):881-8. PubMed ID: 14554016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modern possibilities of bioterrorism diagnosis].
    Grzesiowski P; Szafraniec S; Chmylak B; Tylewska-Wierzbanowska S; Hryniewicz W
    Pol Merkur Lekarski; 2003 Feb; 14(80):142-5. PubMed ID: 12728676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioterrorism. Clinical recognition and primary management.
    Branda JA; Ruoff K
    Am J Clin Pathol; 2002 Jun; 117 Suppl():S116-23. PubMed ID: 14569808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopotentiation for bacterial biodefense.
    Skyberg JA
    Curr Top Med Chem; 2014; 14(18):2115-26. PubMed ID: 25373479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of eleven commercially available rapid tests for detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis.
    Zasada AA; Formińska K; Zacharczuk K; Jacob D; Grunow R
    Lett Appl Microbiol; 2015 May; 60(5):409-13. PubMed ID: 25598285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tularemia, a potential bioterrorism weapon].
    Bossi P; Bricaire F
    Presse Med; 2003 Jul; 32(24):1126-30. PubMed ID: 12947746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioterrorism: pathogens as weapons.
    Anderson PD; Bokor G
    J Pharm Pract; 2012 Oct; 25(5):521-9. PubMed ID: 23011963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recognition and management of bioterrorism infections.
    O'Brien KK; Higdon ML; Halverson JJ
    Am Fam Physician; 2003 May; 67(9):1927-34. PubMed ID: 12751654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthrax, tularemia, plague, ebola or smallpox as agents of bioterrorism: recognition in the emergency room.
    Cunha BA
    Clin Microbiol Infect; 2002 Aug; 8(8):489-503. PubMed ID: 12197871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.
    Peterson JW; Moen ST; Healy D; Pawlik JE; Taormina J; Hardcastle J; Thomas JM; Lawrence WS; Ponce C; Chatuev BM; Gnade BT; Foltz SM; Agar SL; Sha J; Klimpel GR; Kirtley ML; Eaves-Pyles T; Chopra AK
    Open Microbiol J; 2010 Jun; 4():34-46. PubMed ID: 21127743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Francisella tularensis as a potential agent of bioterrorism?
    Maurin M
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):141-4. PubMed ID: 25413334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen.
    Pappas G; Seitaridis S; Akritidis N; Tsianos E
    Int J Antimicrob Agents; 2004 Nov; 24(5):502-7. PubMed ID: 15519485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous real-time PCR detection of Bacillus anthracis, Francisella tularensis and Yersinia pestis.
    Skottman T; Piiparinen H; Hyytiäinen H; Myllys V; Skurnik M; Nikkari S
    Eur J Clin Microbiol Infect Dis; 2007 Mar; 26(3):207-11. PubMed ID: 17294160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.
    Kennedy JL; Bulitta JB; Chatham-Stephens K; Person MK; Cook R; Mongkolrattanothai T; Shin E; Yu P; Negron ME; Bower WA; Hendricks K
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S379-S391. PubMed ID: 36251546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microbiology laboratory's role in response to bioterrorism.
    Robinson-Dunn B
    Arch Pathol Lab Med; 2002 Mar; 126(3):291-4. PubMed ID: 11860302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo evaluation of fluoroquinolone resistance associated with DNA gyrase mutations in Francisella tularensis, including in tularaemia patients with treatment failure.
    Sutera V; Hoarau G; Renesto P; Caspar Y; Maurin M
    Int J Antimicrob Agents; 2017 Sep; 50(3):377-383. PubMed ID: 28689870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.